The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles
Open accessAbstract
Liver-directed AAV transgene expression is enhanced by ImmTOR nanoparticles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 ImmTOR admixed to AAV provides higher transduction and mRNA and protein expression but similar inhibition of IgG response. (A to D) Groups of C57BL/6 female mice (n = 20) were injected with AAV8-SEAP (5 × 1011 vg/kg) alone or combined with 100 μg of ImmTOR, administered either as an admix or sequentially (non-admix) as shown in experimental scheme (A). Livers were harvested from five mice per group at each time point and analyzed for vector DNA (B) and SEAP mRNA (C). Sera from the same animals were analyzed for SEAP activity (D). Vector genome copies (vg per cell) and SEAP mRNA fold increase [normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH)] over naïve mice. (E) C57BL/6 female mice (n = 10 per group) were injected with AAV8-SEAP (5 × 1011 vg/kg) alone or combined with 100 μg of ImmTOR, either as an admix or administered sequentially. Hepatic vector DNA and SEAP mRNA and serum SEAP levels in the group receiving AAV8-SEAP admixed to ImmTOR versus the other two groups were statistically different at every time point (P < 0.01, except for the 3-day and 7-day time points for vector DNA at P < 0.05, multiple t test), as were anti-AAV IgG levels in groups treated with AAV8-SEAP combined with ImmTOR versus the group receiving AAV8-SEAP alone (P < 0.01, multiple t test).](https://figures.cochat.ai/paper-figures/fa3cf8cbbc2b4177a57ea0c351978a8d/enhancement-of-liver-directed-transgene-expression-at-initial-and-repeat-doses-figure-2.jpg)





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a promising model of coadministration of encapsulated rapamycin (ImmTOR) along with AAV vectors results in decreased capsid-specific humoral response, T cell response, and immune cell infiltration into the target organs, with stable transduction and transgene expression.67”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: mTORC1-Induced HK1-Dependent Glycolysis Regulates NLRP3 Inflammasome Activation
Moon, J.-S., Hisata, S., Park, M.-A., DeNicola, G. M., Ryter, S. W., Nakahira, K., & Choi, A. M. K. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.05.046 · Cited by 374
RetractedAnalysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881 · cited 3×
“(6) recently highlighted immunogenicity and vector potency as two key challenges in the ability to achieve and maintain therapeutic levels of transgene expression.”
BackgroundInfluential
Cited by
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
“217 The ef fi cacy of co-administration of ImmTOR with AAV vectors to control anti-AAV immune responses in patients, as well as potential side effects, will be crucial points for future use in the clinical setting.”
BackgroundrAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
“Other methods include plasmapheresis (57, 58), saline flushing (59), IgG proteases (60), capsid engineering (61–63), and lipid nanoparticle encapsulated rapamycin (64), most of which are under preclinical development.”
BackgroundCAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
Arjomandnejad, M., Kopec, A. L., & Keeler, A. M. (2022) · Biomedicines · doi:10.3390/biomedicines10020287 · Cited by 171
Sands, E., Kivitz, A., DeHaan, W., Leung, S. S., Johnston, L., & Kishimoto, T. K. (2022) · Nature Communications · doi:10.1038/s41467-021-27945-7 · Cited by 61
Self-citationHemophilia A gene therapy: current and next-generation approaches
Pipe, S. W., Gonen-Yaacovi, G., & Segurado, O. G. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2002842 · Cited by 57
“…recently developed to induce immune tolerance and thereby enhance transgene expression after the first dose of an AAV vector and inhibit adaptive antibody and T cell immune responses against the AAV capsid, allowing for repeated administration of AAV vectors in mice and nonhuman primates [120,121].”
Metadata
- Authors
- Ilyinskii, P. O., Michaud, A. M., Roy, C. J., Rizzo, G. L., Elkins, S. L., Capela, T., Chowdhury, A. C., Leung, S. S., & Kishimoto, T. K.
- Affiliations
- Selecta Biosciences (United States) (US)
- Corresponding author
- Kishimoto, Takashi K.
- ORCID
- Venue
- Science Advances
- Published
- 2021-02-26
- Volume
- 7
- Issue
- 9
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC7904260
- OpenAlex
- W3129500930
- Cited by
- 56
- References
- 40
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 9 · 2023: 12 · 2022: 9 · 2021: 8
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- adeno-associated virus vectors, rapamycin, liver-directed gene delivery, repeated dosing, adaptive immunity, inborn errors of metabolism, systemic gene therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.